Skip to main content
. Author manuscript; available in PMC: 2014 Feb 3.
Published in final edited form as: J Am Acad Dermatol. 2013 Jul 18;69(4):570–577. doi: 10.1016/j.jaad.2013.05.019

Fig 1.

Fig 1

Azelaic acid (AzA) inhibits kallikrein 5 (KLK5) expression in differentiated keratinocytes. A, KLK5 protein expression as measured by enzyme-linked immunosorbent assay in keratinocytes grown in basal (low-calcium) medium or differentiated in high-calcium culture conditions. B, KLK5 messenger RNA (mRNA) expression measured by quantitative real-time polymerase chain reaction in both basal and high-calcium growth conditions. AZA cells treated with AzA at 10−8 mol/L. Control cells treated with vehicle (dimethyl sulfoxide [DMSO]) only. *P <.05. Ca2+, Calcium.